GLP1R and Stroke: Secondary analyses of individual MACE components showed that GLP-1 RAs reduced cardiovascular death by 13% (HR 0.87, 95% CI [0.80–0.94], p = 0.001), total MI by 10% (HR 0.90, 95% CI [0.83–0.98], p = 0.020) and total strokes by 17% (HR 0.83, 95% CI [0.76–0.92], p = 0.0002) [9].